Human Papillomavirus (HPV), High Risk by Transcription-Mediated Amplification (TMA), ThinPrep
FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) in women ≥30 years. Follow-up test for abnormal cytology results in women ≥21 years.
Qualitative Transcription-Mediated Amplification
Females should avoid high concentrations of antifungal cream or contraceptive jelly, and should not douche prior to time of collection.
Cervical, anal or vaginal specimens with the ThinPrep Pap Test Collection kit.
Vortex ThinPrep PreservCyt solution and transfer 1 mL to an APTIMA Specimen Transfer Tube (ARUP supply #42711) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.
Specimens in any media other than indicated above.
Specimen source required.
ThinPrep PreservCyt solution: Ambient: 1 month; Refrigerated: 1 month; Frozen: 2 years
APTIMA Specimen Transfer Tube: Ambient: 2 months; Refrigerated: 2 months; Frozen: 2 years
This test detects E6/E7 viral messenger RNA of the high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 associated with cervical cancer and its precursor lesions. Cross-reactivity with low-risk HPV genotypes 26, 67, 70, and 82 may occur. Sensitivity may be affected by specimen collection methods, stage of infection, and the presence of interfering substances. Results should be interpreted in conjunction with other available laboratory and clinical data.
This test is intended for medical purposes only and is not valid for the evaluation of suspected sexual abuse or for other forensic purposes. HPV testing should not be used for screening or management of atypical squamous cells of undetermined significance (ASCUS) in women under age 21.
No compliance statements are in use for this test.
|Component Test Code*||Component Chart Name||LOINC|
|2007891||HPV, High Risk by TMA||49896-4|
- HPV HR E6/E7 TMA
- HPV RNA
- Nucleic Acid Amplification Test (NAAT)